Table 5.
The association between polymorphisms encoding for regulatory and catalytic antioxidant proteins with the risk of disease progression.
| Genotype | Stage I, n (%) |
Stages II + III, n (%) |
OR (95%CI) 1 | p | OR (95%CI) 2 | p |
|---|---|---|---|---|---|---|
| NRF2 (rs6721961) | ||||||
| CC | 43 (72) | 18 (69) | 1.00 3 | 1.00 3 | ||
| CA + AA | 17 (28) | 8 (31) | 1.12 (0.41–3.06) |
0.819 | 0.82 (0.22–3.01) |
0.769 |
| GSTM3 (rs1332018) | ||||||
| AA | 31 (53) | 7 (28) | 1.00 | 1.00 3 | ||
| AC + CC | 27 (47) | 18 (72) | 2.95 (1.07–8.13) |
0.036 | 4.51 (1.30–15.63) |
0.018 |
| SOD2 (rs4880) | ||||||
| CC | 11 (20) | 7 (28) | 1.00 3 | 1.00 3 | ||
| CT + TT | 44 (80) | 18 (72) | 0.64 (0.21–1.92) |
0.429 | 0.389 (0.14–1.45) |
0.160 |
| GPX3 (rs8177412) | ||||||
| TT | 28 (47) | 10 (38) | 1.00 3 | 1.00 3 | ||
| TC + CC | 32 (53) | 16 (62) | 1.40 (0.54–3.58) |
0.482 | 2.21 (0.69–7.09) |
0.182 |
1 OR—crude odds ratio; 2 OR adjusted to other genotypes; IP—confidence interval; 3 reference group.